Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 819-826

  Dressman, Holly K ^a,b   Hans, Christopher ^b   Bild, Andrea ^a,b   Olson, John A ^a   Eric Rosen, P ^a   Marcom, Kelly ^a   Liotcheva, Vlayka B ^a   Jones, Ellen L ^a   Vujaskovic, Zeljko ^a   Marks, Jeffrey ^a   Dewhirst, Mark W ^a   West, Mike ^a,b   Nevins, Joseph R ^a   Blackwell, Kimberly ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EVACET; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; HYPOXIA; LYMPH NODE METASTASIS; MASTITIS; ONCOGENE; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 32944476048     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1447     Document Type: Article

References (22)

1. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-74.
2. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002;59:41-8.
3. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
4. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998;334:1-8.
5. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-7.
6. Fyles A, Voduc D, Syed A, Milosevic M, Pintilie M, Hill R. The effect of smoking on tumour oxygenation and treatment outcome in cervical cancer. Clin Oncol 2002;14:442-6.
7. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
8. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1994;30:635-42.
9. Jones EL, Prosnitz LR, Dewhirst MW, et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res 2004;10:4287-93.
10. Vujaskovic Z, Rosen EL, Blackwell KL, et al. Ultrasound guided p02 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. Int J Hyperthermia 2003;19:498-506.
11. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
12. Pittman J, Huang E, Dressman H, et al. Models for individualized prediction of disease outcomes based on multiple gene expression patterns and clinical data. Proc Natl Acad Sci U S A 2004;101:8431-6.
13. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
14. Ihaka R, Gentleman R. A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
15. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
16. Rich J, Jones B, Hans C, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005;65:8869-77.
17. Hans C, Dobra A, West M. Shotgun stochastic search for regression with many candidate predictors. ISDS Discussion paper 2005.
18. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
19. Cure H, Amat S, Penault-Llorca R, et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat 2002;76:37-45.
20. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041-6.
21. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
22. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.